Harsha Sen, MD
Ophthalmology · Dothan, ALNPI 1255692414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,334 of the $11,123 with a category attached, or 65.9%. Boehringer Ingelheim International GmbH accounts for 65.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $4,797 and has fallen 78.3% since, to $1,040 in 2025. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $65.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$7K
- AbbVie$864
- Genentech USA, Inc.$660
- Alimera Sciences, Inc.$385
- Apellis Pharmaceuticals, Inc.$346
- Regeneron Healthcare Solutions, Inc.$335
- plus $1K from 17 others
Across 54 payments — averaging $2378.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$123K
- Boehringer Ingelheim Finland Ky$6K
What the payments were for
- Speaking & faculty fees$7,33466%
- Food & beverage$3,76934%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 18 | $7,334 |
| AbbVie(2 entities) | 38 | $864 |
| Genentech USA, Inc. | 30 | $660 |
| Alimera Sciences, Inc. | 18 | $385 |
| Apellis Pharmaceuticals, Inc. | 7 | $346 |
| Regeneron Healthcare Solutions, Inc. | 9 | $335 |
| Novartis | 13 | $254 |
| Astellas Pharma US Inc | 6 | $237 |
| Tarsus Pharmaceuticals, Inc. | 9 | $172 |
| Amgen | 1 | $120 |
| ANI Pharmaceuticals, Inc. | 4 | $76 |
| Biogen | 3 | $52 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $46 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Dompe US, Inc. | 1 | $29 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $25 |
| Harrow Eye, LLC | 1 | $19 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Genentech, Inc. | 1 | $11 |
| Heidelberg Engineering, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,123 in reported general payments places this provider in the 90th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 398 | $12,929 |
| LumiganBimatoprost | 21 | $10,415 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $6,530 |
| ProlensaBromfenac Sodium | 13 | $4,582 |
| Ketorolac Tromethamine | 170 | $3,880 |
| Brimonidine Tartrate | 122 | $1,687 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,533 |
| Timolol Maleate | 55 | $1,468 |
| Latanoprost | 154 | $1,463 |
| Valganciclovir Hcl | 11 | $1,315 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 111 | $977 |
| Atropine Sulfate | 15 | $522 |
| Dorzolamide Hcl | 18 | $364 |
| ErythromycinErythromycin Base | 17 | $160 |
| Cyclopentolate Hcl | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $864 | $10,41521 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $46 | $4,58213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Dothan
- Sebastian HeersinkDothan$33K
- Kirk SturridgeDothan$11K
- Aaron McKinleyDothan$8K
- Warren ThompsonDothan$6K
- Marius HeersinkDothan$3K
- Jorge ArangoDothan$3K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.